Document is current
Any future updates will be listed below
-
Authors
Taylor, Sarah A. https://orcid.org/0000-0002-3575-8386
Harpavat, Sanjiv
Gromer, Kyle D.
Andreev, Victor
Loomes, Kathleen M.
Bezerra, Jorge A.
Jarasvaraparn, Chaowapong
Wang, Kasper
Horslen, Simon
Rosenthal, Philip
Teckman, Jeffrey
Valentino, Pamela L.
Ng, Vicky L.
Karpen, Saul J.
Sokol, Ronald J.
Alonso, Estella M.
Mack, Cara L.
,
- License Information
-
More Information
Article History
Received: 13 September 2024
Revised: 25 November 2024
Accepted: 13 December 2024
First Online: 29 January 2025
Competing interests
: SAT serves as a consultant for Ipsen and Mirum Pharma. SH serves on the Data Safety Monitoring Board coordinated by Syneos Health for a therapeutic drug trial for biliary atresia. KML serves as a consultant for Ipsen and Mirum Pharma. PV serves on the Speaker’s Bureau for Mirum and is a consultant for Grifols. SJK serves as a consultant for Ipsen, Hemoshear, Intercept, Mirum, and Vertex. RJS serves as consultant for Ipsen and Mirum Pharma. All remaining coauthors declare no conflicts of interest for this manuscript.
: Written informed consent was obtained for all participants. Institutional review board approval was obtained for the study and conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
